Genetic Leap, a company focused on AI-driven drug discovery, announced Thursday a research collaboration worth up to $409M with Eli Lilly (NYSE:LLY) to develop gene-based therapeutics.

As part of the deal, the duo will leverage Genetic Leap’s RNA-targeted AI platform to develop oligonucleotide drugs for targets selected by Lilly (LLY).

The New York-based biotech said the partnership follows a successful pilot program with LLY. According to the deal’s structure, Genetic Leap is set to receive up to $409M in upfront and milestone payments, in addition to tiered royalties.

“We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines,” said Genetic Leap’s CEO and founder, Bertrand Adanve.

“Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal.”